Clark Capital Management Group Inc. Acquires 90,508 Shares of AbbVie Inc. $ABBV

Clark Capital Management Group Inc. increased its stake in AbbVie Inc. (NYSE:ABBV) by 15.0% in the 3rd quarter, HoldingsChannel reports. The fund owned 695,391 shares of the company’s stock after acquiring an additional 90,508 shares during the period. AbbVie accounts for approximately 1.0% of Clark Capital Management Group Inc.’s holdings, making the stock its 15th largest holding. Clark Capital Management Group Inc.’s holdings in AbbVie were worth $161,011,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. Norges Bank purchased a new position in shares of AbbVie in the 2nd quarter worth approximately $4,288,200,000. Wellington Management Group LLP raised its holdings in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock valued at $2,439,714,000 after buying an additional 8,646,424 shares during the period. Laurel Wealth Advisors LLC lifted its position in AbbVie by 18,384.4% in the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after buying an additional 5,675,095 shares during the last quarter. Vanguard Group Inc. lifted its position in AbbVie by 1.9% in the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after buying an additional 3,380,842 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in AbbVie by 169.3% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after buying an additional 2,969,202 shares during the period. 70.23% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.25% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on ABBV shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $223.00 price objective on shares of AbbVie in a research report on Wednesday, January 28th. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research note on Monday, March 9th. UBS Group cut their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Royal Bank Of Canada started coverage on shares of AbbVie in a research report on Tuesday, February 24th. They issued an “outperform” rating and a $260.00 price objective on the stock. Finally, Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Two analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Phase‑1 data for ABBV‑295 reported as encouraging — supports pipeline optionality beyond core brands and is constructive for long‑term revenue upside. AbbVie Reports Promising Results from Phase 1 Study of ABBV-295
• Positive Sentiment: AbbVie advanced a risankizumab dosing study, signaling continued investment in immunology — reinforces management’s growth strategy in a key therapeutic area. AbbVie Advances Risankizumab Dosing Study, Signaling Ongoing Immunology Investment
• Positive Sentiment: RBC Capital started coverage with an Outperform and $260 price target — a bullish institutional view that supports upside versus current levels. RBC Capital Says AbbVie Inc. (ABBV) Growth Story Is Still in Early Stages
• Positive Sentiment: Consensus analyst stance remains supportive (“Moderate Buy”), which provides a baseline of buy‑side conviction. AbbVie Inc. (NYSE:ABBV) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Allergan Aesthetics‑affiliated providers earned top rankings in NY (beneficial for Allergan Aesthetics’ commercial reputation, but limited immediate impact on ABBV stock). New York Plastic Surgical Group and Deep Blue Med Spa Named #1 in New York by Allergan Aesthetics for the Second Year in a Row
• Neutral Sentiment: Features and listicles (e.g., halal/debt‑free stock roundup, retirement income pieces) mention AbbVie but are peripheral to near‑term price movement. Is AbbVie Inc. (ABBV) One of the Debt Free Halal Stocks to Buy?
• Neutral Sentiment: Market reports forecasting growth in bipolar‑depression therapies expand the market opportunity for psychiatric drugs broadly; indirect for AbbVie unless tied to specific assets. Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
• Negative Sentiment: Shareholder governance concern: reports that the AbbVie CEO’s pay package has spiked above $30M can weigh on sentiment and prompt selling by governance‑focused funds. J&J, AbbVie CEOs See Pay Spike to More Than $30M
• Negative Sentiment: Analyst debate about immunology competition and valuation creates two‑sided risk—some analysts lift targets on growth, others flag competition that could cap upside, encouraging short‑term profit‑taking. How The Narrative For AbbVie (ABBV) Is Shifting On Immunology Growth And Competition Risks

AbbVie Trading Down 2.5%

NYSE:ABBV opened at $219.73 on Friday. The company has a market cap of $388.51 billion, a price-to-earnings ratio of 93.10, a price-to-earnings-growth ratio of 0.76 and a beta of 0.34. AbbVie Inc. has a twelve month low of $164.39 and a twelve month high of $244.81. The stock has a fifty day simple moving average of $224.33 and a 200-day simple moving average of $224.67.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.